Printer friendly version Share

News Release

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

26 June 2014 European Society for Medical Oncology (ESMO)

Please login or register to view articles older than 3 months

Cambridge blue millet eNEWS-Dec 2016 FNSF ad expertsvar 2015 New Norwegian logo Elhuyar with Basque Science Daily